Ibogaine Treatment for
Parkinson's Disease

Medical Consultation & Screening

Comprehensive evaluation of your Parkinson's history, current medications, symptom profile, and neurological status. We work closely with your neurologist to review your case and design a protocol that complements your existing care. Levodopa and dopamine agonist management during treatment requires careful coordination.

Days 1 to 2: Arrival & Stabilization

Arrive in Cozumel. Full medical intake, baseline neurological assessment, and gentle acclimatization. Your medication schedule is carefully managed for optimal ibogaine safety. No rushing. you settle in, we complete our evaluation, and preparation is finalized.

Days 3 to 4: Ibogaine Session

Your primary ibogaine treatment is administered under continuous physician and nursing supervision. The experience lasts 12 to 18 hours. For Parkinson's patients, the experience tends to be introspective and often profoundly meaningful. GDNF upregulation begins during and immediately following the session.

Days 5 to 12: Microdosing & Integration

Structured microdosing sessions every 2 to 3 days sustain the GDNF signaling initiated by the full-dose session. Daily physiotherapy, movement therapy, and exercise amplify neuroregeneration. Nutritional support, sleep optimization, and integration work run throughout.

Days 13 to 14: Assessment & Discharge Planning

Comprehensive neurological reassessment. Comparison with baseline measures. Development of your at-home microdosing protocol and ongoing care plan. Full caregiver briefing. Coordination with your neurologist for continuity of care.

Ongoing: Remote Monitoring & Support

Follow-up consultations at 30, 60, and 90 days post-discharge to assess neurological response, adjust the microdosing protocol, and optimize your at-home regimen. We remain your clinical partners through the critical post-treatment neuroregeneration window.

No. We do not claim that ibogaine cures Parkinson's disease, and we would be doing patients a disservice if we did. What ibogaine offers is a mechanistically sound neuroprotective and potentially neurorestorative intervention through GDNF upregulation. something that conventional Parkinson's therapy does not provide. Many patients experience meaningful improvements in motor function and quality of life. Whether these represent slowing of disease progression or functional compensation through neuroplasticity remains to be established in controlled trials.

This requires careful management and close coordination with your neurologist. Levodopa and dopamine agonist dosing needs to be specifically adjusted around ibogaine administration to ensure safety and optimize outcomes. We do not ask patients to discontinue their Parkinson's medications. we work with your existing care team to manage them appropriately throughout the program.

Patient-reported outcomes have included reductions in tremor, improved rigidity, better gait fluidity, reduced 'off' periods for patients on levodopa, improved sleep, and improved mood and emotional wellbeing. The consistency of motor improvements in the weeks following treatment is what the GDNF mechanism would predict. We document all outcomes and are transparent about the full range of responses we observe.

With appropriate screening and medical supervision, yes. The primary safety considerations for all ibogaine patients. cardiac screening (QTc interval evaluation), medication interactions, and continuous monitoring. apply equally to Parkinson's patients. The complexity of Parkinson's medication management adds an additional layer of medical coordination. Our 14 to 18 day program is specifically designed to provide the level of medical oversight that Parkinson's patients require.

We evaluate each patient individually. More advanced disease does not automatically disqualify a patient. GDNF upregulation can provide neuroprotective benefit at any stage, and functional improvements in motor symptoms have been observed across disease stages. What matters is the medical fitness of the patient to safely undergo treatment, which we assess comprehensively during the screening process.

We provide each patient with a personalized at-home microdosing schedule designed to sustain GDNF signaling beyond the in-program period. The protocol typically involves very low doses of ibogaine-derived compounds administered on a structured schedule over 60 to 90 days. We provide complete guidance on sourcing, administration, and monitoring, with medical follow-up to adjust the protocol based on neurological response.